Author:
Mukhopadhyay Srinjay,Dixit Prithvi,Khanom Najiyah,Sanghera Gianluca,McGurk Kathryn A.
Abstract
AbstractHeart failure (HF) remains a major cause of mortality and morbidity worldwide. Understanding the genetic basis of HF allows for the development of disease-modifying therapies, more appropriate risk stratification, and personalised management of patients. The advent of next-generation sequencing has enabled genome-wide association studies; moving beyond rare variants identified in a Mendelian fashion and detecting common DNA variants associated with disease. We summarise the latest GWAS and rare variant data on mixed and refined HF aetiologies, and cardiomyopathies. We describe the recent understanding of the functional impact of titin variants and highlight FHOD3 as a novel cardiomyopathy-associated gene. We describe future directions of research in this field and how genetic data can be leveraged to improve the care of patients with HF.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference169 articles.
1. Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5. https://doi.org/10.21037/amj.2020.03.03.
2. Benjamin E, Muntner P, Alonso A, Bittencourt M, Callaway C, Carson A. Heart disease and stroke Statistics—2019 update: A report from the american heart association. Circulation. 2019;139:e56–e528.
3. Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O’Donnell CJ. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006;355:138–47.
4. Lindgren MP, PirouziFard M, Smith JG, Sundquist J, Sundquist K, Zöller B. A swedish nationwide adoption study of the heritability of heart failure. JAMA Cardiol. 2018;3:703–10.
5. Tayal U, Prasad S, Cook SA. Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med. 2017;9:20.